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Abstract 
Several distinct fluid flow phenomena occur in solid tumors, including intravascular blood flow 
and interstitial convection. Interstitial fluid pressure is often raised in solid tumors, which can 
limit drug delivery. To probe low-velocity flow in tumors resulting from raised interstitial fluid 
pressure, we developed a novel magnetic resonance imaging (MRI) technique named 
convection-MRI, which uses a phase-contrast acquisition with a dual-inversion vascular 
nulling preparation to separate intra- and extra-vascular flow. Here we report the results of 
experiments in flow phantoms, numerical simulations, and tumor xenograft models to 
investigate the technical feasibility of convection-MRI. We observed a significant correlation 
between estimates of effective fluid pressure from convection-MRI with gold-standard, 
invasive measurements of interstitial fluid pressure in mouse models of human colorectal 
carcinoma. Our results show how convection-MRI can provide insights into the growth and 
responsiveness to vascular-targeting therapy in colorectal cancers. 
 
Precis: A noninvasive method for measuring low-velocity fluid flow caused by raised fluid 
pressure can be used to assess changes caused by therapy. 
 
Keywords: interstitial fluid flow, interstitial fluid pressure, phase contrast MRI, tumor, cancer 
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Introduction 
The convection of fluid in biological tissue is normally associated with intravascular blood flow, 
in which fluid flows from high to lower pressure, at velocities ranging from 5 – 70 cm s-1 in 
arteries (1,2), 0.8-2.5 mm s-1 in capillaries (3) and 1.5 – 28 cm s-1 in veins (1,2). Fluid within 
the interstitium is normally maintained at or just below atmospheric pressure by venous and 
lymphatic vessels (4), and several pathological conditions, including cancer, can disrupt key 
pressure regulation processes, leading to widespread elevated interstitial fluid pressure (IFP) 
(5).  
 
Raised IFP in solid tumors has been the subject of extensive research to investigate its 
pathophysiological consequences, which can include an increased metastatic potential (6-8), 
higher rates of proliferation (9,10) and impaired drug delivery (11-16). It is associated with 
numerous pathophysiological processes in tumors, and has been described as a ‘universal 
generic early-response marker of tumor response to therapy’ (17). A physical consequence of 
raised IFP in tumors is the slow convection of fluid through the interstitium (4), which has been 
widely reported and studied (4,18-21), but is technically challenging to measure, and has only 
been directly assessed through invasive means (22). IFP is normally elevated in the center of 
tumors and maintained close to atmospheric pressure at the periphery by surrounding tissues, 
resulting in the convection of fluid from the center outwards (21), with a velocity in the range 
0.1 to 50 µm s-1 (18). 
  
In this study, we report the development of a new, non-invasive imaging technique that aims 
to probe the slower-flowing components of fluid flow in tumors; in particular, those associated 
with interstitial fluid. It is based on velocity-encoded MRI, with a dual inversion preparation that 
aims to null the faster-flowing vascular signal. We describe our approach in this study, which 
we have named convection-MRI, assess its technical feasibility and evaluate its underlying 
assumptions. Specifically, convection-MRI assumes that: 1) the intravascular signal can be 
completely nulled by dual inversion pulses; 2) velocity encoding is sufficiently sensitive to 
measure the velocity of fluid flow in the interstitium; and 3) the influence of nulled fluid 
exchanging between intra- and extra-vascular compartments is negligible. The physical 
principles underlying the acquisition are described schematically in Supplemental Movie 1. 
Both the dual inversion and velocity-encoding techniques have been used separately in other 
contexts (for example, references (23-25) for the dual inversion preparation and references 
(26,27) for velocity-encoding), but their combined use is novel in the current application, and 
neither has been used to study interstitial flow.  
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The study was undertaken in two distinct mouse xenograft models of colorectal cancer, both 
during their growth and following treatment with a vascular disrupting agent (VDA). The results 
of this multiparametric, noninvasive MRI analysis allowed numerous novel insights into the 
differential growth characteristics of two colorectal cell lines with differing vascular and cellular 
morphology (SW1222 and LS174T) to be gleaned, and how these relationships were modified 
with VDA therapy. SW1222 cells form well-differentiated tumors with glandular structures 
resembling normal colon, and are well-vascularized (28), with minimal hypoxia (29,30). In 
contrast, LS174T tumors are poorly differentiated, with heterogeneously distributed 
vasculature (including avascular regions) (28), and regional hypoxia (29,30), and so provide 
a useful comparative model system. 
 
Materials and Methods 
 
Convection-MRI  
A sequence diagram for the convection-MRI sequence is shown in Supplemental Figure 1, 
which was implemented on a 9.4 T horizontal bore MRI scanner (Agilent, Santa Clara, 
California), with a maximum gradient strength of 1 T m-1. The sequence consisted of two 
modules: a dual inversion-recovery preparation that aimed to null the signal from flowing 
blood, followed by velocity-encoding. The first adiabatic inversion pulse in the vascular nulling 
preparation was applied globally and was followed immediately by a slice-selective inversion 
(thickness 0.3 cm). Inversion pulses were 2 ms in duration, and were separated by 4 μs. A 
T1,blood of 1900 ms was assumed, which was taken from previous measurement in the mouse 
ventricular pool (31). At a time trec following the global inversion pulse, the signal from fluid in 
blood vessels passes a null point, where trec = ln(2)T1,blood (giving trec = 1317 ms for the value 
of T1,blood used here).  
 
Following trec, a standard single-slice gradient echo readout sequence was applied (TE, 2.6 
ms; TR, 2500 ms; flip angle, 30; slice thickness, 1 mm; field of view, 3535 mm2, matrix size, 
128128). The venc parameter is the maximum velocity that can be measured without 
producing phase aliasing, and depends on the amplitude and duration of velocity encoding 
gradients (32). In this study we used gradient amplitude (G) of 300 mT m-1 and gradient 
duration () of 3 ms to give a venc of 2200 μm s-1. Velocity-encoding required two repetitions of 
the sequence, the second of which used bipolar gradients of opposite polarity to the first. The 
difference in the phase shift induced by the gradients, between the two measurements, Δϕ, is 
proportional to fluid velocity, according to the following relationship: 
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Here, v is fluid velocity, γ is the proton gyromagnetic ratio (267.513  106 rad s-1 T-1) and ΔM1 
is the difference in first order velocity-encoding gradient moments (where venc = π/γΔM1 and 
ΔM1 = 2G2). 
 
The convection-MRI sequence was used to measure fluid velocities in two directions, 
corresponding to phase and readout imaging gradient orientations. Total scan duration was 
25 minutes. In-plane fluid velocity vectors were constructed for each pixel and displayed using 
in-house software written in Interactive Data Language (ITT, Boulder, Colorado). A 
streamlining algorithm (iVector) was used to visualise pathways between neighbouring 
velocity vectors, which used points with low velocity relative to the distribution within the image 
as seed points. 
 
Mouse tumor models and in vivo MRI 
All in vivo experiments were approved by a local ethical review panel and the UK Home Office 
Animals Scientific Procedures Act (1986), and were undertaken in accordance with UK 
National Cancer Research Institute (NCRI) guidelines (33). Six-week old MF1 nu/nu mice were 
injected subcutaneously on the midline of the right flank, close to the hind limb (to minimize 
respiration motion during imaging), with 5106 SW1222 or LS174T cells.  
 
MRI was performed following 10 to 15 days’ growth (giving a tumor volume of approximately 
0.6 cm3). Immediately prior to scanning, anesthesia was induced in the mice with 3-4% 
isoflurane carried in O2. Once anaesthesia was confirmed, mice were transferred to a bespoke 
imaging cradle, in which anesthesia was maintained with 1.25 to 1.75% isoflurane, which was 
delivered via a nose cone. Mice were positioned on their side, with tumor uppermost. Tumors 
were liberally covered in dental paste (Charmflex, Dentkist, South Korea), to eliminate bulk 
motion. When set (typically taking 2-3 minutes), the dental paste held the subcutaneous tumor 
tissue in place via contact with the imaging cradle. Once prepared, the cradle was positioned 
in the center of the 9.4T MRI scanner. Throughout imaging, core body temperature was 
monitored and maintained at 36.5 C using a warm air blower and physiological monitoring 
apparaturs (SA Instruments, Stony Brook, NY). Respiratory rate was also monitored and 
maintained at 40 to 60 respirations per minute by varying the isoflurane fraction. RF pulses 
were transmitted and received with a 39 mm birdcage coil (Rapid MR International, Columbus, 
OH). At the end of in vivo experiments, mice were culled via cervical dislocation, and tumor 
tissue was harvested for further analysis. 
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Determining the sensitivity of convection-MRI to low-velocity flow 
To evaluate the ability of the 9.4 T MRI scanner to measure the velocity of fluid travelling at 
velocities of the order of 1 – 100 μm s-1, an imaging phantom was constructed from a 5 mL 
syringe, with an internal diameter of 11 mm (see Figure 1a). This simple phantom provided 
easily controllable fluid velocities, with coherent, laminar flow profiles, that can be compared 
against convection-MRI velocity measurements, to inform subsequent in vivo experiments. A 
syringe driver was used to inject water into the phantom, via silicon tubing that incorporated a 
3 m loop within the scanner bore to allow the flowing water to become fully magnetised. 
Convection-MRI data were acquired with no vascular nulling (i.e. equivalent to a purely 
velocity-encoding sequence) from a sagittal slice through the chamber of the phantom. The 
inflow rate of the phantom was varied between 0.007 and 6.85 mL min-1 (giving a theoretical 
fluid velocity range of 1 to 1000 μm s-1, assuming laminar flow). Convection-MRI data were 
acquired in a cross-section across the phantom, without the vascular nulling preparation. venc 
for these acquisitions was varied between 1000 and 5000 μm s-1, applied in separate 
acquisitions in the read and phase encoding directions. 
 
Evaluation of the efficacy of vascular nulling 
Phantom and in vivo experiments were performed to evaluate the ability of the convection-
MRI sequence to null the signal from fluid flowing within tumor blood vessels. Two sets of 
images were acquired: the first without the vascular nulling (dual inversion) preparation, and 
the second with vascular nulling. Taking the ratio of images acquired with and without vascular 
nulling, referred to as the nulling ratio (nv), enabled vascular volume to be approximately 
estimated (23).  
 
Influence of the assumed value of blood T1 on vascular nulling in tumors 
In a separate cohort of mice bearing SW1222 or LS174T tumors (n = 3 for each), the effect of 
varying trec (equivalent to varying the assumed value of T1,blood) was investigated. Nulling ratio 
maps were produced in each tumor for 17 values of trec, ranging from 100 to 5000 ms. The 
average and standard deviation of the nulling ratio was estimated across the cohort and 
plotted as a function of trec. 
 
Estimation of apparent fluid pressure (Peff) from convection-MRI data 
IFP was estimated from velocity vector fields using Darcy’s law: 
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where K is the hydrostatic conductivity, v fluid velocity and P fluid pressure. To estimate P, 
velocity vector fields, measured using convection-MRI, were numerically integrated using a 
finite difference approach. To define absolute pressure, rather than relative changes in 
pressure, estimates were offset by the average value at the periphery of the tumor, with the 
assumption that the periphery of the tumor is in equilibrium with surrounding normal tissues 
(34). We refer to this as the effective fluid pressure (Peff). Thus, a boundary condition for the 
model was that the mean pressure at the periphery of the tumor is zero. For comparison, direct 
measurement of IFP was performed using a clinical pressure transducer (Stryker, Kalamazoo, 
Michigan, USA), modified to incorporate a 28G needle (34). Samples were acquired at 8 to 12 
locations within each tumor, at depths corresponding to the convection-MRI imaging plane. 
 
The influence of fluid exchange and incomplete vascular nulling on interstitial fluid velocity 
measurements 
To further evaluate nulling efficiency and the influence of nulled fluid entering the interstitium 
on convection-MRI IFV estimates, a series of simulations were performed in the Interactive 
Data Language (IDL, Excelis, Boulder, Colorado). A multi-compartment model of a vascular 
tumor was constructed with a blood volume (fv) of 8%, intracellular volume (fic) 80% and the 
volume of the extracellular extravascular space (EES, fees) 12%, reflecting those values 
previously measured in SW1222 colorectal carcinoma mouse xenograft tumors (35). A single 
voxel within a section of tumor was modelled, with a slice thickness corresponding to that used 
in the convection-MRI sequence.  
 
Tumor blood vessels were modelled as randomly oriented cylinders. The radius of each 
vessel, r, was generated by randomly drawing from a distribution of vessel radii previously 
reported by Burrell et al (35), which we fitted to an exponential probability distribution (p(r) = 
0.15 exp(-70r)). The total blood vessel volume in each simulation was constrained to be within 
10% of the average value (i.e. fv ranged from 7.2 to 8.8%). The pressure drop, ΔP, across 
each vessel was fixed at 2 mm Hg mm-1 and blood viscosity, η, was fixed at 3.5×10-3 N s m-2. 
Blood flow, F, in each vessel was calculated according to the Hagen-Poiseuille equation: 
 


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
           [3] 
 
from which blood velocity, vv, was given by vv = F / d2, where d is the vessel diameter. The 
change in signal phase induced by fluid flowing in each blood vessel, in the presence of 
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velocity-encoding gradients in the x, y or z directions (and with zero baseline phase), was 
given by 
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where |vv| the magnitude of the blood velocity in the vessel, and α, β and γ are the angles of 
the vessel, relative to the x, y and z imaging gradient axes, respectively. The total signal from 
all blood vessels, for velocity-encoding gradients applied in the x-direction (the only direction 
evaluated in the simulations, for simplicity), was then 
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S0,v was fixed at unity and relaxation effects were not modelled. To model the effect of fluid 
nulling in the vascular compartment a factor nv was introduced, which ranged from 0 and 1, 
representing zero to complete nulling. nv was calculated by the fractional volume of nulled fluid 
that replaced un-nulled fluid in blood vessels, at the end of the recovery time following the dual 
inversion pulses. This was given by 
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where a is the thickness of the imaging slice (1 mm) and b is the thickness of the slice-selective 
inversion pulse (3 mm).  
 
Interstitial fluid velocity was varied between 1 and 100 μm s-1 and was directed along the x-
axis, for simplicity. By analogy with the vascular signal, the signal from the interstitial 
compartment, for velocity-encoding gradients applied in the x direction, was 
 
   xeeseeseesxees inSS ,,0, exp1         [7] 
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   and S0,ees was fixed at unity. Simulated nulling of EES fluid was 
performed explicitly, with nees ranging from 0 to 1. The total MR signal S was then given by 
 
iciceeseesvv SfSfSfS          [8] 
 
with 1 iceesv fff  and Sic = 1. 
 
1000 Monte Carlo iterations were performed, within each of which a different distribution of 
blood vessels (drawn from the parent distribution described above) was simulated. As a final 
step, Gaussian noise was added to each set of simulated data to give signal-to-noise 
characteristics comparable to those found in in vivo data. The phase of data simulated with 
velocity-encoding gradients applied in the x-direction was then estimated, converted into a 
velocity estimate, and compared with the simulated EES velocity.  
 
Two sets of simulations were performed. Firstly, the effect of nulled fluid entering the 
interstitium was investigated by varying nees between 0 (no nulling) and 1 (complete nulling). 
Intravascular nulling, nv, was calculated according to Eq. 5, allowing the theoretical efficacy of 
vascular nulling to also be determined. In the second set of simulations, to ascertain the 
influence of un-nulled fluid in the vascular compartment on convection-MRI measurements, nv 
was explicitly scaled between 0 and 1, and nees was fixed at 0. 
 
Arterial spin labelling 
Arterial spin labeling (ASL) data were acquired using a flow-sensitive alternating inversion 
recovery (FAIR) Look-Locker ASL sequence, with a single-slice spoiled gradient echo readout 
(36,37) (echo time, 1.18 ms; inversion time spacing, 110 ms; first inversion time, 2.3 ms; 50 
inversion recovery readouts; 4 averages, all geometric parameters matched to the convection-
MRI acquisition). FAIR-ASL does not require a labelling artery to be identified, and instead 
uses two acquisitions with different inversion preparations: the first, a global inversion pulse, 
inverts all spins; the second a localized, slice-selective pulse inverts spins within the tissue of 
interest (a 3 mm slice thickness was used here). The difference between these two signals 
can be used to measure perfusion, and here regional perfusion maps were calculated as 
described by Belle et al. (38), with an assumed blood-partition constant of 0.9. As for 
convection-MRI measurements, the T1 longitudinal relaxation time of blood was assumed to 
be 1900 ms (39). FAIR-ASL data were acquired in a single slice located in the same position 
as convection-MRI data. 
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Diffusion MRI 
Diffusion MRI data were acquired using a fast spin-echo sequence with geometry matched to 
convection-MRI data. The sequence contained the following parameters: repetition time (TR), 
1500 ms; echo train, 4; echo time spacing, 7.74 ms; 5 b-values (150, 300, 500, 750, 1050 s 
mm-2, all applied in the slice-select direction). Diffusion-weighted (magnitude) data were fitted 
to a single exponential model of the form 
 
𝑆 = 𝑆0𝑒
−𝑏.𝐴𝐷𝐶        [9] 
 
on a pixel-by-pixel basis, using a Bayesian maximum a posteriori approach that takes into 
account the Rician distribution of magnitude MRI data (40). b is the b-value associated with 
each diffusion-weighted acquisition, and S is the acquired signal magnitude for each pixel. 
Maps of each fitted parameter (the apparent diffusion coefficient (ADC) and S0) were 
generated. 
 
Dynamic contrast-enhanced MRI 
Gadolinium-DTPA (Magnevist, Bayer, Leverkusen, Germany) was prepared to a 
concentration of 0.2 mM (factor of 10 dilution) and transferred to a 50 mL Falcon tube. This 
was placed in a power injector (Harvard Instruments, Cambourne, UK), positioned inside the 
scanner room, with a 2 m tube attached, feeding into an 18 G plastic cannula. The dead 
volume of the tubing was primed with contrast agent and the cannula positioned within the 
intraperitoneal cavity. Contrast agent was infused at 0.005 mmol kg-1 min-1 for the duration of 
the scan (total dose 0.2 mMol kg-1). A gradient-echo sequence was used to acquire three-
dimensional contrast-enhancement data (TE, 2.43 ms; TR, 107 ms; flip angle 20°; 20 slices; 
slice thickness 0.5 mm; matrix size, 128×128; FOV, 35×35 mm; temporal resolution 12.8 s; 2 
averages), both prior to the start of the infusion, and 40 minutes later. The change in signal 
intensity induced by contrast agent was calculated by subtracting the baseline signal from the 
post-infusion data, on a pixel-by-pixel basis, and expressed as a percentage. Contrast 
enhancement under this infusion protocol will depend on the volume accessible to Gd-DTPA 
and interstitial transport characteristics (e.g. interstitial fluid pressure and conductivity) (34). 
 
Microvascular casting 
Microvascular casting was performed for colocation of the convection-MRI and perfusion MRI 
with the tumor vasculature. Casting was performed immediately following MRI. Briefly, the 
heart was exposed and a blunted 25G butterfly cannula was inserted through the heart and 
into the ascending aorta. 10 mL of saline was injected through the cannula using a syringe 
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driver (Harvard Instruments, MA, USA). Once the saline injection was complete, casting 
material (Microfil, Flowtech, Boston, USA) was injected via the same cannula at 60 mL hr-1. 
The microfil used was colored yellow and could be seen entering the vascular bed of the 
subcutaneous tumors; perfusion of resin was continued until no further coloration of tumor 
vasculature occurred (typically around 25 mL of resin in total, of which a significant proportion 
is lost as waste). Following perfusion, the resin was allowed to completely polymerise, which 
took approximately two hours. Tumors were then carefully resected from the mouse carcass, 
mounted in chlorine-free plastic food wrap inside a 20 mL syringe (Sigma-Aldrich, Gillingham, 
Dorset), with plunger removed, and sent for micro-CT.  
 
Micro-CT was performed on a Skyscan 1172 (Bruker, Massachusetts, USA). Images were 
acquired over 360° at rotation steps of 0.2 degrees. Exposure was set to 590 ms per frame, 
and source voltage and current values were 49 kV and 200 µA, respectively. The data were 
reconstructed with Nrecon software (version 1.6.6.0, SkyScan). Reconstruction duration was 
1.48 s per slice, with ring artifact correction set to 6. Image pixel size was 8.3 μm. 
 
Results 
 
Evaluation of fluid velocity measurements in a flow phantom 
The first experiment aimed to assess the sensitivity of the convection-MRI sequence to low-
velocity flow, using a simple flow phantom. Velocity measurements, with the vascular nulling 
preparation switched off and using a venc of 1000, 2000 and 5000 μm s-1, in separate 
experiments. Theoretical velocity predictions were estimated from the known fluid inflow rate 
and phantom diameter, and assumed laminar flow profiles. Fluid flow was directed from the 
point of inflow of the phantom, to the point of outflow (left to right in the image in Figure 1a), 
and was greatest in a channel through the centre of the phantom (Figure 1b).  
 
For venc of 2000 and 5000, velocity measurements were significantly correlated with theoretical 
velocity predictions (p<0.01, Spearman’s rho), for a range of physiological inflow values 
(Figure 1). At lower venc values, aliasing occurred at higher velocity values (resulting in 
significantly lower velocity estimates; denoted by arrows on Figure 1c), and signal crushing 
by velocity gradients (particularly at venc ≤ 500 µm s-1). At the largest inflow rate (6.85 mL min-
1, theoretical velocity 1000 µm s-1), significant spatial wrapping was found in raw velocity 
encoded data, for the majority of venc values used, so this data point was disregarded. 
 
Whilst, for venc ≥ 2000 µm s-1, convection-MRI velocity measurements were significantly 
correlated with theoretical estimates, they displayed a slight overestimation (15 ± 23 %, based 
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on the y-intercept of the regression line) (Figure 1c). The minimum flow rate that could be 
measured before the signal approached the noise background level, was 0.07 mL min-1 
(corresponding to a velocity of 20 m s-1). 
 
Evaluation of vascular nulling in tumors 
The convection-MRI sequence was next evaluated in vivo, using subcutaneous mouse tumor 
xenograft models (SW1222 and LS174T human colorectal carcinoma cell lines). Our first 
objective was to assess the efficacy of the vascular nulling component. As the preparation 
aims to destroy the signal from fluid flowing in blood vessels, taking the ratio of images 
acquired with and without vascular nulling (the nulling ratio) allowed us to approximately 
estimate the vascular blood volume (23). In subcutaneous colorectal xenograft models 
(SW1222 and LS174T, n = 4 for each), the measured nulling ratio ranged from 0 to 80% and 
was heterogeneously distributed throughout the tumors (Figure 2a). On average, vascular 
nulling induced a decrease in signal of 18% in SW1222 and 13% in LS174T tumors, a 
difference that was significantly different (p < 0.05, Mann-Whitney). No nulling was observed 
in a static agar phantom, as expected, due to the absence of flowing fluid (Figure 2a).  
 
Plotting the mean nulling ratio as a function of the assumed blood longitudinal relaxation time 
(T1,blood), from in vivo experiments in SW1222 tumors (n = 4), revealed a plateau centred at 
1900 ms at which the signal decrease caused by nulling was maximal (Figure 2b), suggesting 
that vasculaing nulling was most effective for an assumed T1,blood = 1900 ms (and so was used 
throughout the remainder of the study). 
 
Measurement of fluid velocity in tumors 
 
Complete sets of convection-MRI data (i.e. with both vascular nulling and velocity encoding) 
were next acquired in SW1222 and LS174T tumors (n = 6 for both) (Figs. 3a to n). Plotting 
fluid velocity vectors for each pixel in the tumors revealed macroscopic flow patterns (Figure 
3e and l), which often extended across the entirety of the tumor. These patterns were further 
visualised using a streamlining algorithm (Figs. 3f and m) that connected paths of coherent 
interstitial fluid flow, and revealed flow from a single or multiple sources within each tumor, 
towards the periphery. This source was generally located either towards the centre of the 
tumor or at the interface with the abdominal wall. Streamlines were often observed to be 
directed radially from the source, towards the outermost edge of the tumor. We measured fluid 
speeds of 10 to 220 m s-1 (95th percentiles), with mean fluid speed of 110  55 m s-1 and 
170  80 m s-1 (mean standard error) for SW1222 and LS174T tumors, respectively. These 
velocity measurements are significantly greater than those associated solely with interstitial 
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flow (typically < 1 μm s-1 (18)). An assessment of measurement repeatability and 
reproducibility is provided in the supplemental materials (Supplemental Figure 2, 
Supplemental Table 1). 
 
Numerical simulations of tumor fluid dynamics 
 
Monte Carlo simulations of tumor fluid dynamics were performed using physiological 
measurements previously reported in the literature. Figure 4a shows a schematic diagram of 
the simulations. The Hagen-Poiseuille equation used in these simulations estimated fluid 
velocities in blood vessels in the range of 0.2 to 15 mm s-1, which contrasts with the much 
slower fluid velocities in the interstitium (explicitly varied between 1 and 100 μm s-1).  
 
In the first set of simulations, it was found that nv was consistently greater than 99.9%, for 
each set of parameter values, suggesting that vascular nulling in this type of tumor is feasible. 
A fraction of the interstitial fluid was explicitly nulled to represent leakage of nulled fluid from 
the vasculature, and unintentional nulling of the interstitial fluid signal. Under these conditions, 
the accuracy of IFV measurements was unaffected by the nulling of interstitial fluid (Figure 
4b), but precision progressively decreased with increased nulling (evidenced by the increasing 
standard error shown in Figure 4b). This loss of precision was caused by the decrease in 
signal-to-noise ratio resulting from the nulling, although the value of the simulated IFV had no 
influence on the magnitude of this effect. 
 
In the second set of simulations, a progressive, incomplete nulling was imposed on the 
vascular fluid. It was found that both the accuracy and precision of IFV measurements became 
poorer as the fractional nulling of vascular fluid decreased (Figure 4c). The mean relative 
error in velocity measurements was 15%, 50% and 115% for 95%, 80% and 50% vascular 
nulling, respectively. As shown in Figure 4c, incomplete vascular nulling introduced a 
progressive offset to velocity measurements, but the gradient of each line is constant. 
 
Estimation of fluid pressure and comparison with a direct measurement with a pressure 
transducer  
Convection-MRI provides measurements of fluid velocity vectors (i.e. with both direction and 
magnitude), from which we inferred an effective pressure (Peff) using Darcy’s Law of fluid flow 
in a permeable medium. Mean Peff from convection-MRI measurements was 13  2 mm Hg in 
SW1222 tumors and 16  5 mm Hg in LS174T tumors, which were not significantly different 
(p > 0.05). Example velocity and apparent pressure images are shown in Figs. 5a and b. 
Plotting the mean effective pressure value from the centre of each tumor, measured with 
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convection-MRI, against those from pressure transducer measurements at corresponding 
locations, revealed a significant correlation (r2 = 0.77, p < 0.05, Figure 5c). On average, 
convection-MRI pressure measurements from the centre of tumors were 26% larger than 
those from the pressure transducer, and this over-estimation was larger at low IFP values. In 
these calculations, a fixed value was used for the hydrostatic conductivity (4.13×10-8 cm2 mm 
Hg-1 s-1 (4)). 
 
Comparison of tumor blood flow and fluid velocity distributions 
Next, the coupling of intravascular and interstitial flow was probed, in a set of experiments in 
which measurements of tumor fluid velocity were acquired with convection-MRI, alongside 
measurements of vascular perfusion from arterial spin labelling (ASL) MRI. These were 
accompanied by high resolution images blood vessels acquired ex vivo from vascular casts at 
high spatial resolution (6 μm), with micro-CT.  
 
Our first observation was that regions of high vascular perfusion (Figure 6a) measured in vivo 
coincided with highly vascular regions at the periphery of both tumor types, as assessed by 
microvascular casting (Figure 6b, Supplemental Movies 2-4). Vascular perfusion was 
significantly greater in SW1222 tumors than in LS174T tumors (0.28  0.16 mL g-1 min-1 and 
0.15  0.11 mL g-1 min-1, respectively, p < 0.01, Wilcoxon rank sum). This is consistent with 
the known vascular characteristics of each tumor type (29,30). Furthermore, as shown in the 
examples in Figures 6b, fluid velocity streamlines were found to emanate from highly perfused 
regions at the periphery of the tumors and follow paths through the interstitium that avoid other 
vascular regions. In the case of the example LS174T tumor shown in Figure 6b, interstitial 
fluid streamlines converged at the centre of the tumor and exited at a single, avascular point 
at the tumor periphery.  
 
The relationship between blood flow and interstitial convection was also explored by 
administering an exogenous contrast agent (gadolinium-DTPA) that could be independently 
visualised with MRI, and which is delivered via the tumor vasculature. The top row (first image) 
of Figure 6c shows an example LS174T tumor, in which raised accumulation of contrast agent 
can be observed between the two lobes that constituted the tumor (an animated version is 
provided in Supplemental Movie 5). Streamlines from convection-MRI measurements 
revealed interstitial flow in opposing directions through the two lobes, which converged at their 
common boundary (Figure 6c, top row), corresponding to the region of raised contrast agent 
accumulation (blue arrow). According to a separate ASL measurement, vascular perfusion in 
this region was low, thereby implicating it as a sink for interstitial drainage, rather than the 
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contrast agent being supplied directly by the tumor vasculature. In the bottom row of Figure 
6c, data from a second LS174T tumor is shown, in which a region with poor contrast agent 
uptake is demarked by a blue arrow, with raised effective pressure. This therefore describes 
an opposite scenario to that of the first tumor, in which a region of raised IFP is potentially 
inhibiting the uptake of the contrast agent. Both of these examples demonstrate the potential 
of convection-MRI and ASL, in combination, to describe the uptake of exogenously 
administered agents (which could potentially be extended to therapeutic agents). 
 
The relationship between vascular perfusion and effective fluid pressure during tumor growth 
The mechanisms that initiate and maintain raised IFP in tumors are of particular interest, and 
so we performed a further experiment that aimed to measure fluid velocity, effective fluid 
pressure and perfusion in tumors during growth from a small size (10 days following 
inoculation, defined as day 0), for a total of 10 days (Figure 7a). We found no significant 
difference in the mean growth rates for SW1222 and LS174T tumors, which were measured 
from tumor volume estimates using high-resolution T2-weighted MRI. Investigating the 
relationship between each parameter and tumor volume revealed a significant inverse 
correlation between vascular perfusion and tumor volume, whilst fluid velocity and effective 
pressure were both positively correlated with tumor volume (p < 0.05, Figures 7b). As necrosis 
is generally more evident in LS174T tumors than in SW1222 tumors, it might be expected that 
the measured apparent diffusion coefficient (ADC) would be correspondingly larger; however, 
there was no significant difference between the two tumor types, which is consistent with our 
previous measurements (30).  
 
Assessment of response to therapy with a vascular disrupting agent 
At the end of the growth experiment, and immediately following the final MRI measurement, 
we administered a single dose of the vascular disrupting agent CA4P (100 mg kg-1) to all mice. 
Previous studies have shown that this rapidly induces vascular occlusion and haemorrhage 
(41), and a corresponding change in perfusion and IFP (42). With this in mind, we measured 
the change in perfusion, Peff and fluid velocity at 24 hours following dosing. As expected, tumor 
volume did not change significantly with CA4P dosing, whilst perfusion significantly decreased 
(p<0.01 in LS174T and p<0.05 in SW1222). Fluid velocity significantly increased in LS174T 
tumors (p < 0.05)) and Peff significantly decreased in SW1222 tumors (p < 0.05) (Figure 7c). 
Tumor ADC significantly increased at 24 hours after dosing, in both tumor types, presumably 
due to the onset of necrosis (p < 0.05). 
 
Discussion 
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We have proposed here a new technique named convection-MRI, which aims to measure low-
velocity fluid flow in tumors, using phase contrast MRI, by first nulling the fast-flowing 
intravascular signal with a dual-inversion preparation. The aim of this study was to evaluate 
whether convection-MRI could directly measure the velocity of interstitial fluid. In order to 
achieve this a number of assumptions associated with the measurement would need to be 
validated, and we aimed to evaluate the most significant of these in this study. We then used 
convection-MRI to study low-velocity fluid flow in tumor xenograft models, which appeared to 
reveal macroscopic flow patterns that were consistent with the flow of fluid through the tumor 
interstitium, albeit at velocities greater than those normally associated with interstitial flow. 
 
In tumor xenograft models of human colorectal cancer, we calculated mean fluid velocity 
estimates of 110  55 m s-1 and 170  80 m s-1 in SW1222 and LS174T tumors, respectively, 
which is larger than those recorded in tumors using other techniques. A review by Munson et 
al reports IFV values of the order of 0.1 to 55 m s-1, measured using a range of techniques, 
both in mouse tumor models and human patients (18). On this basis, the slowest flowing 
components of interstitial fluid would appear to be inaccessible with this technique, particularly 
as our flow phantom measurements could detect a minimum velocity of 20 μm s-1. It is worth 
also noting that measurements of the lowest velocity components (i.e. around 20 μm s-1) will 
be associated with a greater uncertainty, due to the influence of noise. The presence of fluid 
velocities greater than 55 μm s-1 in our in vivo measurements is potentially due to 
contamination by faster-flowing vascular fluid. This therefore presents a challenge for the 
interpretation of convection-MRI data, as it cannot reasonably be claimed that velocity 
measurements are entirely interstitial in origin, nor that the entire range of interstitial flow 
velocities can be captured.  
 
These observations were further explored through Monte Carlo simulations of a SW1222 
tumors, which predicted vascular nulling of greater than 99.9%, for all sets of physiological 
parameters considered. They also showed that un-nulled vascular fluid can, in principle, be 
entirely replaced by nulled fluid within the recovery time trec between vascular nulling and 
velocity encoding. In the simulations, straight tumor vessels were modelled, whilst real tumor 
vessels are likely to take more tortuous paths, thereby potentially explaining the disparity 
between our simulation results and the fluid velocities measured in vivo (43). Sensitivity to 
these slower flowing components (and improved specificity towards interstitial flow) could 
therefore potentially be achieved by improving vascular nulling for slow-flowing blood, and 
increasing the acquisition venc. 
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Whilst not an explicit component of the convection-MRI acquisition, in vivo estimates of blood 
volume were also derived by comparing nulled and un-nulled images. This analysis provided 
blood volume estimates that were greater than, but of the order of the microvascular density 
previously reported for these tumor types. Previous studies provide average blood volumes of 
between 9 (44) and 25% (30) for SW1222 and 8 (30) to 9% (45) for LS174T tumors, whereas 
we measured an average percentage vascular nulling of 18% and 13% for SW1222 and 
LS174T tumors, respectively. The largest blood volume values were measured at the tumor 
periphery (of the order of 80%), where vessels tend to be larger and more concentrated (29), 
which demonstrates the ability of convection-MRI to capture the spatial heterogeneity of tumor 
vasculature. These data could therefore act as a useful complement to the convection-MRI 
acquisition, although requires the acquisition of the additional un-nulled image. 
 
Despite our velocity measurements being greater than those previously reported in the 
literature, we still found a significant correlation between Peff (derived from the spatial 
derivative of velocity measurements) and measurements of IFP measured directly with a 
pressure transducer, although with a 26% overestimation (Figure 5c). We used Darcy’s Law 
to quantify pressure from velocity vector fields, which is widely used in the modelling of fluid 
dynamics in biological tissue. It is valid for systems with a low Reynolds number which, in 
tumors, is typically much less than 1 (46). When estimating absolute pressure from velocity 
vector fields, pressure boundary conditions are required, and here we assumed that the mean 
interstitial pressure at the periphery of tumors was maintained at atmospheric pressure (34). 
Equally, we used a fixed value for the hydrostatic conductivity of tumor tissue, K. K provides 
a linear scaling to pressure estimates (as per Darcy’s Law in equation 2), and so errors 
associated with this value will therefore introduce a linear offset into pressure estimates. As K 
can only currently be measured by invasive means, use of a fixed value is presently the only 
available solution. Our assessment of repeatability and reproducibility (36% and 59%) were 
slightly larger, but of the order of those measured for other MRI techniques (e.g.  13% - 62% 
for diffusion MRI (47) and 8.9 to 18.2 % for dynamic contrast-enhanced MRI (48)). This 
variability, both in the magnitude and direction of velocity vectors, should be taken into account 
in future development or application work using the technique, although further work is 
required to determine if it is reflective of true physiological changes in interstitial and/or 
vascular transport over short timeframes. For example, it is well-known that tumor blood flow 
and oxygenation can change over short timeframes (49-51), and this could potentially have 
similarly transient effects on interstitial flow. 
 
We next probed the relationship between microvascular perfusion and interstitial fluid 
pressure, which has not been extensively studied, mainly due to a lack of available, non-
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invasive techniques. Our measurements, acquired over a period of ten days of tumor growth, 
revealed differences in the microenvironments of two colorectal tumor types. We found that 
perfusion on average decreased with tumor volume, whilst effective fluid pressure increased, 
which is in agreement with previous studies (20,52). Both low vascular perfusion and raised 
IFP can act as a barrier to drug delivery, our combined approach would allow these properties 
to be probed simultaneously and monitored longitudinally. Generally, LS174T tumors are more 
necrotic than SW1222 tumors, at 59 ± 4 % and 10 ± 3 %, respectively, in fully-grown tumors 
(53), and which likely increases to these levels throughout tumor growth. Large regions of 
central necrosis occurs at 24 hours following dosing with CA4P (54). However, the presence 
of necrosis should not affect the convection-MRI acquisition (instead, it could be of interest to 
study further, to investigate the influence of necrosis on interstitial fluid pressure and drug 
delivery).  
 
We have also shown here that ASL and convection-MRI, in combination, can be used to 
assess response to the vascular disrupting agent CA4P. The decrease in Peff that we observed 
in SW1222, and no significant change in LS174T tumors, is in agreement with the decrease 
or stasis found in other studies. It is of interest that SW1222 exhibited a minimal decrease in 
perfusion with CA4P treatment, compared with the response in LS174T, yet still exhibited a 
decrease in Peff and increase in ADC. This could be due to complex changes in tumor fluid 
dynamics, which could be of interest to further explore. 
 
A number of studies have compared other imaging-based parameters with pressure 
transducer measurements of IFP, such as dynamic contrast enhanced MRI (8,34) and/or 
diffusion MRI (55). These have generally shown a correlation with IFP, but such relationships 
are not necessarily causal and could rely on associations with other aspects of tumor 
pathophysiology. However, the uptake of contrast agent has previously been shown to 
correlate with the uptake of chemotherapeutic drugs (56) and to probe interstitial transport and 
lymphatic drainage (57), and convection-MRI could compliment these approaches via its 
ability to directly measure the flow of interstitial fluid within tumors. Some attempts have been 
made to quantify IFP from contrast agent studies (58,59), and a study comparing this approach 
and the convection-MRI technique would be useful. It is worth noting that our calculation of 
the nulling time within the convection-MRI signal model, assumed complete recovery of the 
longitudinal magnetisation within a practical acquisition recovery time. However, a more 
accurate estimate could be used that takes into account for incomplete recovery of the 
longitudinal magnetisation. Simulations using the Bloch equations suggest that this effect 
introduces small (approximately 3%) error into the vascular nulling efficiency, but which could 
be utilised in future studies. 
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Translation of the convection-MRI sequence onto clinical systems should be straightforward, 
although requires further investigation and numerical simulations. Factors such as signal-to-
noise and resolution differences between the high-field experimental system used here and 
that of clinical MRI systems would need to be explored. Equally, whether the approach offers 
sufficient sensitivity to the slowest fluid flows in the clinical setting would need to be evaluated, 
and tumor motion during scanning would need to be minimised. Conversely, T1 is shorter at 
clinical field strengths, allowing a shorter in-flow time during vascular nulling (although human 
blood T1 is longer than in mice). 
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Figure Captions 
 
Figure 1. Evaluation of fluid velocity measurements in a flow phantom. (a) Photograph of the 
fluid velocity flow phantom, based on a 5 mL syringe. The black, dashed box shows the 
approximate location of the imaging plane used. (b) Fluid velocity vector field, acquired from 
a slice through the flow phantom, color-coded to reflect the fluid speed, and with the direction 
characterised using a streamlining algorithm (black lines). (c) The average velocity in the 
center of the phantom is shown plotted against the inflow rate (error bars show the standard 
deviation in each measurement), for venc ranging from 5000 to 250 μm s-1. A significant linear 
correlation was measured for venc values of 5000 and 2000 μm s-1 (p < 0.01). At small venc, 
aliasing was noted at higher inflow rates (marked with arrows), alongside signal crushing 
(particularly evident at venc = 250 μm s-1). Each data point on the graph corresponds to the 
average value measured in 20 to 30 voxels in the phantom. 
 
Figure 2. Evaluation of vascular nulling in tumor xenograft models. (a) Example maps showing 
the nulling ratio (the ratio of images acquired with vascular nulling to one acquired without 
vascular nulling) in an agar phantom and two different tumors. In the agar phantom, the nulling 
ratio was zero (top row), as expected due to the absence of flowing fluid. (b) A plot of the 
average nulling ratio as a function of the assumed blood longitudinal relaxation time (T1,blood). 
The assumed value of T1,blood is used to set the recovery time following the inversion 
preparation (trec = ln(2) T1,blood). The graph shows that, for a range of T1,blood of 1600 to 2500 
ms, the nulling ratio is maximal. At lower values, the nulling is lower as the signal from blood 
has not recovered to a null point; at larger values, the signal has recovered past the null. The 
plateau represents a region where the signal from blood is near to or at the null point and has 
sufficient time to flow into and replace unlabelled blood within the imaging slice. 
 
Figure 3. Example convection-MRI data sets (both raw image data and processed image 
data) in two example LS174T tumor xenografts: representative magnitude (a, h) and phase 
(b, i) images; maps of the change in phase with velocity-encoding gradients applied in vertical 
(readout) (c, j) and horizontal (phase-encoding) (d, k) directions. Velocity vector maps (e, l) 
show the direction of fluid transport through the tumor interstitium, which is better visualised 
using a streamlining algorithm (f, m) to connect pathways of coherent fluid convection (bottom 
row, colored arrows). Streamlines are color-coded to reflect the local fluid speed, which is also 
represented in histograms (g, n). 
 
Figure 4. Results of simulations of fluid flow in SW1222 tumors. (a) shows a schematic 
diagram of the multi-compartment simulations (not to scale), in which red tubes represent 
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blood vessels, yellow spheres are cells and the yellow cuboid represents the imaging slice. 
Parameters from the numerical simulation are overlaid. In (b), the mean value of IFV is plotted 
as a function of the percentage nulling of the interstitial fluid, for three simulated velocity values 
(0.02, 0.05 and 0.1 mm s-1). Error bars show the standard error in the mean value from 1000 
Monte Carlo simulations. The graph in (c) shows IFV plotted against simulated interstitial 
velocity, for four vascular fractional nulling values (100, 95, 80 and 50%). Error bars show the 
standard error in the mean. 
 
Figure 5. Estimation of effective fluid pressure (Peff) from convection-MRI measurements. a) 
An example convection-MRI fluid velocity streamline map and b) the corresponding effective 
pressure map from the same SW1222 tumor. c) Measurements of mean effective fluid 
pressure with convection-MRI, vs direct measurement of interstitial fluid pressure with a 
pressure transducer. Each point corresponds to the mean pressure in a different tumor, and 
error bars represent the standard error. Convection-MRI and pressure transducer 
measurements were significantly correlated (p < 0.05, Spearman’s rho). 
 
Figure 6. Comparison of perfusion (measured using arterial spin labelling) and convection-
MRI measurements. (a) Perfusion maps in SW1222 tumors (left and right) and an LS174T 
tumor (centre). ASL measurements are shown as heatmaps, and are overlaid with black 
streamlines showing the measured path followed by fluid within tumors. (b) Fluid flow 
measured in vivo with convectionMRI are shown as grey streamlines and perfusion is shown 
as a colorscale. The location of blood vessels is represented by yellow volume renderings, 
acquired using ex vivo microvascular casting and imaged with micro-CT. Data are shown in 
example LS174T (left) and SW1222 (right) tumors. In the SW1222 tumor, larger vessel 
structures in the centre of the tumor could be due to swelling by the casting material, although 
it is unclear if these vessels would have also been swollen under normal physiological 
conditions. A high-resolution version is provided in Supplemental Figure 3. (c) The 
relationship between fluid flow, vascular perfusion and the delivery of a medium molecular 
weight contrast agent in two LS174T tumors. Left column: Uptake of Gd-DTPA, an MRI 
contrast agent; middle column: vascular perfusion maps (color scale) overlaid with interstitial 
convection streamlines (grey); right column: effective pressure measurements from fluid 
mechanical modelling of convection-MRI data. The blue arrow in the top row shows a region 
between two lobes of the tumor in which the contrast agent preferentially accumulates, 
interstitial convection streamlines converge, a limited vascular supply is evident, and has a 
low IFP. In the bottom row, a blue arrow highlights a region with limited contrast agent uptake, 
a limited vascular supply, and with raised IFP. Both examples show the ability of convection-
MRI and ASL, in combination, to identify regions that preferentially accumulate or resist the 
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accumulation of exogenously administered agents. This could potentially be extended to the 
prediction of the uptake of therapeutic agents. 
 
Figure 7. Tumor growth and response to therapy characterised with convection-MRI. (a) 
Example maps of vascular perfusion, effective pressure (Peff), fluid velocity and apparent 
diffusion coefficient (ADC) during 10 days of growth in two colorectal tumor xenografts 
(LS174T and SW1222), and at 24 hours following a single dose of the vascular disrupting 
agent CA4P (100 mg kg-1). (b) Scatter plots of the mean values of these parameters, from the 
whole tumor cohort. Fluid speed, measured using convection-MRI, tends to increase with 
tumor volume), whilst perfusion and Peff decrease. Each point corresponds to a single 
measurement from a tumor, and black and grey lines connect individual tumors (LS174T (n = 
6) and SW1222 (n = 7) colorectal tumor xenografts, respectively). (c) shows the mean change 
in each parameter at 24 hours following treatment with CA4P. Tumor volume did not 
significantly change with treatment, whilst in LS174T tumors, perfusion decreased and 
interstitial fluid speed and ADC increased. In SW1222 tumors, perfusion and Peff significantly 
decreased and ADC significantly increased.  Error bars represent the standard error in the 
mean; ** denotes p<0.01, * denotes p<0.05. 
